Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-β levels in APP/PS1 transgenic mice

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 2, 2015, Pages 421-430

  Ordóñez Gutiérrez, Lara ^a   Re, Francesca ^b   Bereczki, Erika ^c   Ioja, Eniko ^c   Gregori, Maria ^b   Andersen, Alina J ^d   Antón, Marta ^a   Moghimi, S Moein ^d,e   Pei, Jin Jing ^c   Masserini, Massimo ^b   Wandosell, Francisco ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Alzheimer treatment; Amyloid ; APP PS1; Nanoparticles

Indexed keywords

BLOOD; ENZYME ACTIVITY; GLYCOPROTEINS; LIPOSOMES; MAMMALS; NANOPARTICLES; NEURODEGENERATIVE DISEASES; PHOSPHOLIPIDS;

ALZHEIMER; ALZHEIMER'S DISEASE; GLYCOGEN SYNTHASE KINASE-3; INTRAPERITONEAL INJECTIONS; INTRAPERITONEALLY; NEUROFIBRILLARY TANGLES; PHOSPHATIDIC ACIDS; SMALL UNILAMELLAR VESICLE;

BRAIN;

AMYLOID BETA PROTEIN; CARDIOLIPIN; CARDIOLIPIN LIPOSOME; GLYCOGEN SYNTHASE KINASE 3; LIPOSOME; PHOSPHATIDIC ACID; PHOSPHATIDIC ACID LIPOSOME; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELL PROLIFERATION; CELL VACUOLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REPEATED DRUG DOSE; ALZHEIMER DISEASE; ANIMAL; BLOOD; BRAIN; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CARDIOLIPINS; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INJECTIONS, INTRAPERITONEAL; LIPOSOMES; MICE; MICE, TRANSGENIC; NANOPARTICLES; PHOSPHATIDIC ACIDS; TAU PROTEINS;

EID: 84922768493     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.09.015     Document Type: Article

References (50)

1. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Psychiatr Psych Gerichtl Med 1907, 64:146-148.
2. Selkoe D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001, 3(1):75-80.
3. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13(1):45-53.
4. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
5. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992, 1(5):345-347.
6. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375(6534):754-760.
7. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995, 269(5226):973-977.
8. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003, 23(1):29-33.
9. Sutcliffe J.G., Hedlund P.B., Thomas E.A., Bloom F.E., Hilbush B.S. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J Neurosci Res 2011, 89(6):808-814.
10. Biscaro B., Lindvall O., Hock C., Ekdahl C.T., Nitsch R.M. Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice. J Neurosci 2009, 29(45):14108-14119.
11. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J Neurochem 2004, 89(4):807-811.
12. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295(5563):2264-2267.
13. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001, 98(15):8850-8855.
14. Tassa C., Duffner J.L., Lewis T.A., Weissleder R., Schreiber S.L., Koehler A.N., et al. Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. Bioconjug Chem 2010, 21(1):14-19.
15. Ramos-Cabrer P., Campos F. Liposomes and nanotechnology in drug development: focus on neurological targets. Int J Nanomedicine 2013, 8:951-960.
16. Gobbi M., Re F., Canovi M., Beeg M., Gregori M., Sesana S., et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 2010, 31(25):6519-6529.
17. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 2001, 17(6):157-165.
18. Senior J., Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci 1982, 30(24):2123-2136.
19. Gregori M., Cassina V., Brogioli D., Salerno D., De Kimpe L., Scheper W., et al. Stability of Abeta (1-42) peptide fibrils as consequence of environmental modifications. Eur Biophys J 2010, 39(12):1613-1623.
20. Re F., Cambianica I., Sesana S., Salvati E., Cagnotto A., Salmona M., et al. Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. J Biotechnol 2010, 156(4):341-346.
21. Cazzaniga E., Bulbarelli A., Lonati E., Orlando A., Re F., Gregori M., et al. Abeta peptide toxicity is reduced after treatments decreasing phosphatidylethanolamine content in differentiated neuroblastoma cells. Neurochem Res 2011, 36(5):863-869.
22. Re F., Cambianica I., Zona C., Sesana S., Gregori M., Rigolio R., et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine 2011, 7(5):551-559.
23. Golde W.T., Gollobin P., Rodriguez L.L. A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim 2005, 34(9).
24. Schmidt S.D., Nixon R.A., Mathews P.A. ELISA method for measurement of amyloid-β levels. Methods Mol Biol 2005, 299. [[Internet]. [279-97 pp.]].
25. Ordóñez-Gutiérrez L., Torres J.M., Gavin R., Antón M., Arroba-Espinosa A.I., Espinosa J.C., et al. Cellular prion protein modulates beta-amyloid deposition in aged APP/PS1 transgenic mice. Neurobiol Aging 2013, 34(12):2793-2804.
26. Andersen A.J., Robinson J.T., Dai H., Hunter A.C., Andresen T.L., Moghimi S.M. Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano 2013, 7(2):1108-1119.
27. Moghimi S.M., Hamad I., Andresen T.L., Jorgensen K., Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006, 20(14):2591-2593.
28. Avila J., Gomez de Barreda E., Engel T., Lucas J.J., Hernandez F. Tau phosphorylation in hippocampus results in toxic gain-of-function. Biochem Soc Trans 2010, 38(4):977-980.
29. Lee V.M., Brunden K.R., Hutton M., Trojanowski J.Q. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 2011, 1(1):a006437.
30. Braithwaite S.P., Stock J.B., Lombroso P.J., Nairn A.C. Protein phosphatases and Alzheimer's disease. Prog Mol Biol Transl Sci 2012, 106:343-379.
31. Moghimi S.M., Parhamifar L., Ahmadvand D., Wibroe P.P., Andresen T.L., Farhangrazi Z.S., et al. Particulate systems for targeting of macrophages: basic and therapeutic concepts. J Innate Immun 2012, 4(5-6):509-528.
32. Allen T.M., Hansen C.B., Guo L.S. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim Biophys Acta 1993, 1150(1):9-16.
33. Moghimi S.M. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials 2006, 27(1):136-144.
34. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53(2):283-318.
35. Moghimi S.M., Hunter A.C., Andresen T.L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012, 52:481-503.
36. Moghimi S.M., Farhangrazi Z.S. Nanomedicine and the complement paradigm. Nanomedicine 2013, 9(4):458-460.
37. Akinyemi R.O., Mukaetova-Ladinska E.B., Attems J., Ihara M., Kalaria R.N. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr Alzheimer Res 2013, 10(6):642-653.
38. Vinters H.V. Cerebral amyloid angiopathy. A critical review. Stroke 1987, 18(2):311-324.
39. Malm T., Koistinaho J., Kanninen K. Utilization of APPswe/PS1dE9 transgenic mice in research of Alzheimer's disease: focus on gene therapy and cell-based therapy applications. Int J Alzheimers Dis 2011, 2011:517160.
40. Langer F., Eisele Y.S., Fritschi S.K., Staufenbiel M., Walker L.C., Jucker M. Soluble Abeta seeds are potent inducers of cerebral beta-amyloid deposition. J Neurosci 2011, 31(41):14488-14495.
41. Griffiths H.H., Whitehouse I.J., Baybutt H., Brown D., Kellett K.A., Jackson C.D., et al. Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. J Biol Chem 2011, 286(38):33489-33500.
42. Alonso-Nanclares L., Merino-Serrais P., Gonzalez S., DeFelipe J. Synaptic changes in the dentate gyrus of APP/PS1 transgenic mice revealed by electron microscopy. J Neuropathol Exp Neurol 2013, 72(5):386-395.
43. McClean P.L., Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 2013, 57-67.
44. El-Husseini A.E., Schnell E., Chetkovich D.M., Nicoll R.A., Bredt D.S. PSD-95 involvement in maturation of excitatory synapses. Science 2000, 290(5495):1364-1368.
45. Ishiyama N., Lee S.H., Liu S., Li G.Y., Smith M.J., Reichardt L.F., et al. Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell-cell adhesion. Cell 2010, 141(1):117-128.
46. Yoshiike Y., Kimura T., Yamashita S., Furudate H., Mizoroki T., Murayama M., et al. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One 2008, 3(8):e3029.
47. Kouchi Z., Barthet G., Serban G., Georgakopoulos A., Shioi J., Robakis N.K. p120 catenin recruits cadherins to gamma-secretase and inhibits production of Abeta peptide. J Biol Chem 2009, 284(4):1954-1961.
48. Himmelstein D.S., Ward S.M., Lancia J.K., Patterson K.R., Binder L.I. Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther 2012, 136(1):8-22.
49. Hernandez F., Gomez de Barreda E., Fuster-Matanzo A., Lucas J.J., Avila J. GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol 2010, 223(2):322-325.
50. Okazawa H., Estus S. The JNK/c-Jun cascade and Alzheimer's disease. Am J Alzheimers Dis Other Demen 2002, 17(2):79-88.